Can induce exogenous cyclic ACTH-dependent Cushing syndrome
[1]
Blocks programmed cell death protein 1 (PD-1)
Enhances T-cell–mediated immune response
Biologic immunotherapy agent
Administered intravenously
[2]
Cancer treatment (e.g., melanoma)
Associated with endocrine side effects like cyclic Cushing
[1]
Treatment of various advanced cancers
Investigated in combination with olaparib for mCRPC
Immunotherapy for biomarker-unselected metastatic prostate cancer
[2]
Classification by use
Immunotherapies
Medications causing endocrine disorders
[1]
Chemicals used as immune checkpoint inhibitors
Chemicals used in cancer immunotherapy
Biologic agents used in combination cancer therapy
[2]
A trustworthy factory and manufacturer
[Cite:1] Osilodrostat for Cyclic Cushing Disease, AACE Endocrinology and Diabetes, Volume 13, Issue 1, January–February 2026, Pages 17-21
[Cite:2] PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis, European Urology Open Science, Volume 84, February 2026, Pages 1-12
